SEC Form 4/A · accession 0001192482-19-000092

Recro Pharma, Inc. · REPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Officer — Chief Financial Officer

Period of report

Jan 18, 2019

Accepted (ET)

Feb 19, 2019 · 4:12 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001588972

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F5	Jan 18, 2019	A	12,857	$0.00	A	25,878	D
Common Stock^F2	Jan 20, 2019	A	5,750	—	A	31,628	D
Common Stock^F3	Jan 20, 2019	F	1,880	$7.99	D	29,748	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F5,F4	$7.99	Jan 18, 2019	A	60,000	A	—	Jan 18, 2029	Common Stock	60,000	60,000	D

F1All of the shares of common stock are represented by restricted stock units that will vest in four equal annual installments beginning January 18, 2020, subject to continued employment with the Company. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.
F2On January 20, 2019, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to 5,750 performance-based restricted stock units granted in a prior year, which were converted into 5,750 shares of common stock on a one-for-one basis.
F3Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
F4The stock option vests in equal monthly installments over 48 months, beginning on the date that is one month from the date of grant, subject to continued employment with the Company.
F5Due to a clerical error, the reporting person is filing this Amendment to correct the number of options and restricted stock units granted.